Celldex Therapeutics, Inc. 8-K Filing

FAQ

Key Financial Figures

• $0.001 — f the Company's common stock, par value $0.001 (the "Common Stock"), at a price to the
• $29.00 — on Stock"), at a price to the public of $29.00 per share (the "Offering"). The net pro
• $282 m — fering are expected to be approximately $282 million, after deducting underwriting dis

Filing Documents

• tm267111d2_8k.htm (8-K) — 32KB
• tm267111d2_ex1-1.htm (EX-1.1) — 251KB
• tm267111d2_ex5-1.htm (EX-5.1) — 9KB
• tm267111d2_ex99-1.htm (EX-99.1) — 10KB
• tm267111d2_ex99-2.htm (EX-99.2) — 12KB
• tm267111d2_ex99-1img01.jpg (GRAPHIC) — 15KB
• tm267111d2_ex99-2img001.jpg (GRAPHIC) — 4KB
• 0001104659-26-038882.txt ( ) — 578KB
• cldx-20260401.xsd (EX-101.SCH) — 3KB
• cldx-20260401_lab.xml (EX-101.LAB) — 33KB
• cldx-20260401_pre.xml (EX-101.PRE) — 22KB
• tm267111d2_8k_htm.xml (XML) — 3KB

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement. On April 1, 2026, Celldex Therapeutics, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the "Underwriters"), relating to the offering, issuance and sale of 10,345,000 shares (the "Shares") of the Company's common stock, par value $0.001 (the "Common Stock"), at a price to the public of $29.00 per share (the "Offering"). The net proceeds to the Company from the Offering are expected to be approximately $282 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The Offering is expected to close on or about April 6, 2026, to 1,551,750 additional shares of Common Stock at the purchase price per Share to be paid by the Underwriters (the "Option"). The Offering is being made pursuant to a prospectus supplement, dated April 1, 2026 (the "Prospectus Supplement"), to be filed with the Securities and Exchange Commission (the "SEC"), and an accompanying base prospectus that forms a part of the Company's automatically effective shelf registration statement on Form S-3 (File No. 333-275300) previously filed with the SEC. The Underwriting Agreement contains customary representations, warranties and agreements by the Company, conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and ma

01 Other Events

Item 8.01 Other Events. On April 1, 2026, the Company issued a press release regarding the launch of the Offering. On April 1, 2026, the Company also issued a press release announcing that it had priced the Offering. Copies of the launch press release and pricing press release are filed as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

Forward-Looking Statements

Forward-Looking Statements Current Report on Form 8-K regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may involve risks and uncertainties, such as statements related to the anticipated closing of the Offering, the amount of proceeds expected from the Offering and the potential exercise by the Underwriters of the Option. The risks and uncertainties involved include the Company's ability to satisfy certain conditions to the closing of the Offering on a timely basis or at all, as well as other risks detailed from time to time in the Company's SEC filings, including in its annual filing on Form 10-K filed with the SEC on February 25, 2026 and the Prospectus Supplement.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement, dated April 1, 2026, by and among Celldex Therapeutics, Inc. and Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein 5.1 Opinion of Lowenstein Sandler LLP 23.1 Consent of Lowenstein Sandler LLP (contained in Exhibit 5.1) 99.1 Press Release dated April 1, 2026 99.2 Press Release dated April 1, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CELLDEX THERAPEUTICS, INC. Dated: April 2, 2026 By: /s/ Sam Martin Name: Sam Martin Title: Senior Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR